A detailed introduction to the diseases that Dasatinib tablets mainly treat

Dasatinib (Dasatinib) is an oral multi-target tyrosine kinase inhibitor mainly used to treat certain types of leukemia, especially chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its mechanism of action is to inhibit the activity of BCR-ABL kinase and block abnormal signal transduction, thereby inhibiting the proliferation of cancer cells and promoting their apoptosis. The advent of dasatinib has greatly improved the treatment prospects for patients with these diseases.

Chronic myeloid leukemia is one of the main indications for dasatinib. For patients in the early chronic phase, accelerated phase and blast phase of myeloid leukemia, dasatinib can effectively control disease progression and prolong the progression-free survival and overall survival rate of patients. Especially for patients who are resistant or intolerant to first-generation tyrosine kinase inhibitors (such as imatinib), dasatinib provides an important treatment option.

In addition, dasatinib is approved for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Patients with this type of leukemia usually have a poor prognosis. The targeted therapy of dasatinib helps improve the treatment effect of patients and delay the progression of the disease. It is also often used in combination chemotherapy regimens to improve the overall effect of treatment.

In addition to leukemia, dasatinib has also shown potential efficacy in other hematological diseases in some clinical studies, but its main applications are still focused on chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Patients should strictly follow the doctor's instructions when using dasatinib and regularly monitor the efficacy and side effects to obtain the best therapeutic effect.

Reference materials:https://www.drugs.com/